- Experience with the use of bortezomib (Velcade) in the Czech Republic since 20042011 | Faculty of Medicine in Hradec Králové
- Bortezomib as the therapy of the multiple myeloma first relapse +12009 | Faculty of Medicine in Hradec Králové
- Bortezomib as the therapy of the multiple myeloma first relapse2009 | First Faculty of Medicine
- Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma +12008 | First Faculty of Medicine
- Bortezomib in multiple myeloma - perspectives2007 | First Faculty of Medicine
- Bortezomib in multiple myeloma patients after allogeneic stem cells transplantation2010 | Central Library of Charles University
- Bortezomib in multiple myeloma patients after allogeneic stem cells transplantation2010 | Faculty of Medicine in Pilsen
- Intrapleural Bortezomib for the Therapy of Myelomatous Pleural Effusion: A Case Report2012 | First Faculty of Medicine
- Bortezomib - the 1st proteasome inhibitor in clinical practise2004 | First Faculty of Medicine
- Bortezomib - the 1st proteasome inhibitor in clinical practisePublication without faculty affiliation
- Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.2008 | First Faculty of Medicine
- Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma2008 | Faculty of Medicine in Hradec Králové
- Bortezomib (Velcade) in Relapsed/Refractory Multiple Myeloma The First Experience in the Czech Republic2005 | First Faculty of Medicine
- The Proteasome Inhibitor Bortezomib (Velcade) in he Treatment of Relapsed/Refractory Multiple Myeloma. The First Experience in the Czech Republic2005 | First Faculty of Medicine
- Final report of University Hospital Hradec Kralove to the clinical trial protocol no. 54767414MMY3004Publication without faculty affiliation
- Treatment results in patients with myelomarelated renal impairment2016 | Faculty of Medicine in Hradec Králové
- Bortezomib - the first proteasome inhibitor in clinical practise2003 | First Faculty of Medicine
- Effect of bortezomib in breast cancer cell linesPublication without faculty affiliation
- IgA pemphigus associated with monoclonal gammopathy completely resolved after achievement of complete remission of multiple myeloma with bortezomib, cyclophosphamide and dexamethasone regimen2010 | First Faculty of Medicine
- Final report of University Hospital Hradec Kralove to the clinical trial protocol no. MK-0683-088Publication without faculty affiliation
- Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial2010 | First Faculty of Medicine
- Bortezomid in the first line therapy2009 | First Faculty of Medicine
- The first experience with bortezomib multiple myeloma therapy in Czech republic +1Publication without faculty affiliation
- Treatment response to bortezomib in multiple myeloma correlates with plasma hepatocyte growth factor concentration and bone marrow thrombospondin concentration2010 | First Faculty of Medicine
- Proteasome inhibitors in the treatment of multiple myeloma2021 | Faculty of Medicine in Hradec Králové
- Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma2016 | First Faculty of Medicine
- Final report of University Hospital Hradec Kralove to the clinical trial protocol no. 54767414MMY3007Publication without faculty affiliation